Correction to: “Melatonin suppresses platelet activation and function against cardiac ischemia/reperfusion injury via PPARγ/FUNDC1/mitophagy pathways”, (J. Pineal Res, (2017), 63, (e12438), 10.1111/jpi.12438);Melatonin suppresses platelet activation and function against cardiac ischemia/reperfusion injury via PPARγ/FUNDC1/mitophagy pathways

Journal of Pineal Research

Volumn 63, Issue 4, 2017, Pages

  Zhou, Hao ^a,b   Li, Dandan ^a   Zhu, Pingjun ^a   Hu, Shunying ^a   Hu, Nan ^b   Ma, Sai ^b   Zhang, Ying ^a   Han, Tianwen ^a   Ren, Jun ^b   Cao, Feng ^a   Chen, Yundai ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

Author keywords

cardiac I R injury; FUNDC1; melatonin; mitophagy; platelet; PPAR

Indexed keywords

ADENOSINE TRIPHOSPHATE; AUTOPHAGY RELATED PROTEIN 5; BECLIN 1; CREATINE KINASE MB; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FUN14 DOMAIN CONTAINING 1; GELATINASE B; HEPARIN; INTERLEUKIN 6; INTERLEUKIN 8; LC3 II PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1; MELATONIN; MONOCYTE CHEMOTACTIC PROTEIN 1; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; SERUM ALBUMIN; TROPONIN T; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; FUNDC1 PROTEIN, MOUSE; MEMBRANE PROTEIN; MITOCHONDRIAL PROTEIN;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT RETRACTION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOWN REGULATION; DRUG MECHANISM; ENERGY METABOLISM; ENERGY YIELD; FLOW CYTOMETRY; GENE DELETION; HEART FUNCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICROTHROMBUS; MITOCHONDRIAL RESPIRATION; MITOPHAGY; MOUSE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PLATELET REACTIVITY; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRANSMISSION ELECTRON MICROSCOPY; TUNEL ASSAY; UPREGULATION; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY;

ANIMALS; MELATONIN; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MITOCHONDRIAL DEGRADATION; MITOCHONDRIAL PROTEINS; MYOCARDIAL REPERFUSION INJURY; PLATELET ACTIVATION; PPAR GAMMA; SIGNAL TRANSDUCTION;

EID: 85027726279     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12947     Document Type: Erratum

References (62)

1. Cornel JH, Ohman EM, Neely B, et al. Relationship of platelet reactivity with bleeding outcomes during long-term treatment with dual antiplatelet therapy for medically managed patients with non-ST-segment elevation acute coronary syndromes. J Am Heart Assoc. 2016;5:e003977.
2. Kidd SK, Bonaca MP, Braunwald E, et al. Universal classification system type of incident myocardial infarction in patients with stable atherosclerosis: observations from thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2 degrees P)-TIMI 50. J Am Heart Assoc. 2016;5:e003237.
3. Han Y, Jing J, Tu S, et al. ST elevation acute myocardial infarction accelerates non-culprit coronary lesion atherosclerosis. Int J Cardiovasc Imaging. 2014;30:253-261.
4. Zhou SS, Tian F, Chen YD, et al. Combination therapy reduces the incidence of no-reflow after primary per-cutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction. J Geriatr Cardiol. 2015;12:135-142.
5. Aldrovandi M, Hinz C, Lauder SN, et al. DioxolaneA3-phosphatidylethanolamines are generated by human platelets and stimulate neutrophil integrin expression. Redox Biol. 2017;11:663-672.
6. Kung PH, Hsieh PW, Lin YT, et al. HPW-RX40 prevents human platelet activation by attenuating cell surface protein disulfide isomerases. Redox Biol. 2017;13:266-277.
7. Hu S, Zhu Y, Zhang Y, et al. Management and outcome of patients with acute coronary syndrome caused by plaque rupture versus plaque erosion: an intravascular optical coherence tomography study. J Am Heart Assoc. 2017;6:e004730.
8. Randriamboavonjy V, Mann WA, Elgheznawy A, et al. Metformin reduces hyper-reactivity of platelets from patients with polycystic ovary syndrome by improving mitochondrial integrity. Thromb Haemost. 2015;114:569-578.
9. Wilkins HM, Koppel SJ, Bothwell R, et al. Platelet cytochrome oxidase and citrate synthase activities in APOE epsilon4 carrier and non-carrier Alzheimer's disease patients. Redox Biol. 2017;12:828-832.
10. Salimi S, Lewis JP, Yerges-Armstrong LM, et al. Clopidogrel improves skin microcirculatory endothelial function in persons with heightened platelet aggregation. J Am Heart Assoc. 2016;5:e003751.
11. Ravi S, Johnson MS, Chacko BK, et al. Modification of platelet proteins by 4-hydroxynonenal: potential mechanisms for inhibition of aggregation and metabolism. Free Radic Biol Med. 2016;91:143-153.
12. Siewiera K, Kassassir H, Talar M, et al. Higher mitochondrial potential and elevated mitochondrial respiration are associated with excessive activation of blood platelets in diabetic rats. Life Sci. 2016;148:293-304.
13. Reinthaler M, Braune S, Lendlein A, et al. Platelets and coronary artery disease: interactions with the blood vessel wall and cardiovascular devices. Biointerphases. 2016;11:029702.
14. Zhang W, Siraj S, Zhang R, et al. Mitophagy receptor FUNDC1 regulates mitochondrial homeostasis and protects the heart from I/R injury. Autophagy. 2017;13:1080-1081.
15. Pelletier-Galarneau M, Hunter C, Ascah KJ, et al. Randomized trial comparing the effects of ticagrelor versus clopidogrel on myocardial perfusion in patients with coronary artery disease. J Am Heart Assoc. 2017;6:e005894.
16. Lin C, Chao H, Li Z, et al. Melatonin attenuates traumatic brain injury-induced inflammation: a possible role for mitophagy. J Pineal Res. 2016;61:177-186.
17. Fuhrmann DC, Brune B. Mitochondrial composition and function under the control of hypoxia. Redox Biol. 2017;12:208-215.
18. Zhang W, Ren H, Xu C, et al. Hypoxic mitophagy regulates mitochondrial quality and platelet activation and determines severity of I/R heart injury. Elife. 2016;5:e21407.
19. Jang JY, Min JH, Wang SB, et al. Resveratrol inhibits collagen-induced platelet stimulation through suppressing NADPH oxidase and oxidative inactivation of SH2 domain-containing protein tyrosine phosphatase-2. Free Radic Biol Med. 2015;89:842-851.
20. Han D, Huang W, Li X, et al. Melatonin facilitates adipose-derived mesenchymal stem cells to repair the murine infarcted heart via the SIRT1 signaling pathway. J Pineal Res. 2016;60:178-192.
21. He B, Zhao Y, Xu L, et al. The nuclear melatonin receptor RORalpha is a novel endogenous defender against myocardial ischemia/reperfusion injury. J Pineal Res. 2016;60:313-326.
22. Itani N, Skeffington KL, Beck C, et al. Melatonin rescues cardiovascular dysfunction during hypoxic development in the chick embryo. J Pineal Res. 2016;60:16-26.
23. Pei HF, Hou JN, Wei FP, et al. Melatonin attenuates postmyocardial infarction injury via increasing Tom70 expression. J Pineal Res. 2017;62:e12371.
24. Zhou H, Zhang Y, Hu S, et al. Melatonin protects cardiac microvasculature against ischemia/reperfusion injury via suppression of mitochondrial fission-VDAC1-HK2-mPTP-mitophagy axis. J Pineal Res. 2017;63:e12413.
25. Chuang JI, Pan IL, Hsieh CY, et al. Melatonin prevents the dynamin-related protein 1-dependent mitochondrial fission and oxidative insult in the cortical neurons after 1-methyl-4-phenylpyridinium treatment. J Pineal Res. 2016;61:230-240.
26. Akbiyik F, Ray DM, Gettings KF, et al. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood. 2004;104:1361-1368.
27. Ali FY, Hall MG, Desvergne B, et al. PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha–brief report. Arterioscler Thromb Vasc Biol. 2009;29:1871-1873.
28. Khanolkar MP, Morris RH, Thomas AW, et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus–an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis. 2008;197:718-724.
29. Liu Y, Park JM, Chang KH, et al. AMP-activated protein kinase mediates the antiplatelet effects of the thiazolidinediones rosiglitazone and pioglitazone. Mol Pharmacol. 2016;89:313-321.
30. Vevera J, Fisar Z, Nekovarova T, et al. Statin-induced changes in mitochondrial respiration in blood platelets in rats and human with dyslipidemia. Physiol Res. 2016;65:777-788.
31. Shao G, Tian Y, Wang H, et al. Protective effects of melatonin on lipopolysaccharide-induced mastitis in mice. Int Immunopharmacol. 2015;29:263-268.
32. Rhee YH, Ahn JC. Melatonin attenuated adipogenesis through reduction of the CCAAT/enhancer binding protein beta by regulating the glycogen synthase 3 beta in human mesenchymal stem cells. J Physiol Biochem. 2016;72:145-155.
33. Zou W, Rohatgi N, Chen TH, et al. PPAR-gamma regulates pharmacological but not physiological or pathological osteoclast formation. Nat Med. 2016;22:1203-1205.
34. Barbosa-da-Silva S, Souza-Mello V, Magliano DC, et al. Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice. Life Sci. 2015;127:73-81.
35. Zhou H, Hu S, Jin Q, et al. Mff-dependent mitochondrial fission contributes to the pathogenesis of cardiac microvasculature ischemia/reperfusion injury via induction of mROS-mediated cardiolipin oxidation and HK2/VDAC1 disassociation-involved mPTP opening. J Am Heart Assoc. 2017;6:e005328.
36. Randriamboavonjy V, Schrader J, Busse R, et al. Insulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway. J Exp Med. 2004;199:347-356.
37. Fleming I, Schulz C, Fichtlscherer B, et al. AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemost. 2003;90:863-871.
38. Liu Y, Oh SJ, Chang KH, et al. Antiplatelet effect of AMP-activated protein kinase activator and its potentiation by the phosphodiesterase inhibitor dipyridamole. Biochem Pharmacol. 2013;86:914-925.
39. Onselaer MB, Oury C, Hunter RW, et al. The Ca(2+)/calmodulin-dependent kinase kinase beta-AMP-activated protein kinase-alpha1 pathway regulates phosphorylation of cytoskeletal targets in thrombin-stimulated human platelets. J Thromb Haemost. 2014;12:973-986.
40. Zhou H, Li D, Shi C, et al. Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro. Sci Rep. 2015;5:12898.
41. Zhou H, Yang J, Xin T, et al. Exendin-4 enhances the migration of adipose-derived stem cells to neonatal rat ventricular cardiomyocyte-derived conditioned medium via the phosphoinositide 3-kinase/Akt-stromal cell-derived factor-1alpha/CXC chemokine receptor 4 pathway. Mol Med Rep. 2015;11:4063-4072.
42. Kohler D, Straub A, Weissmuller T, et al. Phosphorylation of vasodilator-stimulated phosphoprotein prevents platelet-neutrophil complex formation and dampens myocardial ischemia-reperfusion injury. Circulation. 2011;123:2579-2590.
43. Zhang Y, Zhou H, Wu W, et al. Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca(2+)-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways. Free Radic Biol Med. 2016;95:278-292.
44. Shavadia J, Welsh R, Gershlick A, et al. Relationship between arterial access and outcomes in ST-elevation myocardial infarction with a pharmacoinvasive versus primary percutaneous coronary intervention strategy: insights from the STrategic reperfusion early after myocardial infarction (STREAM) study. J Am Heart Assoc. 2016;5:e003559.
45. Feng T, Yundai C, Ying Z, et al. Atherosclerotic plaque morphology indicates clinical symptoms of plaque progression. Cardiology. 2014;129:207-212.
46. Yang X, Gai L, Dong W, et al. Characterization of culprit lesions in acute coronary syndromes compared with stable angina pectoris by dual-source computed tomography. Int J Cardiovasc Imaging. 2013;29:945-953.
47. Zhu H, Xue H, Wang H, et al. Risk stratification and prognostic value of grace and timi risk scores for female patients with non-st segment elevation acute coronary syndrome. Int J Clin Exp Med. 2015;8:4038-4044.
48. Bishop-Bailey D. The platelet as a model system for the acute actions of nuclear receptors. Steroids. 2010;75:570-575.
49. Ray DM, Spinelli SL, O'Brien JJ, et al. Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease. BioDrugs. 2006;20:231-241.
50. Yu L, Fan C, Li Z, et al. Melatonin rescues cardiac thioredoxin system during ischemia-reperfusion injury in acute hyperglycemic state by restoring Notch1/Hes1/Akt signaling in a membrane receptor-dependent manner. J Pineal Res. 2017;62:e12375.
51. Dominguez-Rodriguez A, Abreu-Gonzalez P, de la Torre-Hernandez JM, et al. Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: results of the melatonin adjunct in the acute myocardial infarction treated with angioplasty trial. J Pineal Res. 2017;62:e12374.
52. Zhao Y, Xu L, Ding S, et al. Novel protective role of the circadian nuclear receptor retinoic acid-related orphan receptor-alpha in diabetic cardiomyopathy. J Pineal Res 2017;62:e12378.
53. Nduhirabandi F, Lamont K, Albertyn Z, et al. Role of toll-like receptor 4 in melatonin-induced cardioprotection. J Pineal Res. 2016;60:39-47.
54. Hu J, Zhang L, Yang Y, et al. Melatonin alleviates postinfarction cardiac remodeling and dysfunction by inhibiting Mst1. J Pineal Res. 2017;62:e12368.
55. Girish KS, Paul M, Thushara RM, et al. Melatonin elevates apoptosis in human platelets via ROS mediated mitochondrial damage. Biochem Biophys Res Commun. 2013;438:198-204.
56. Rodella LF, Favero G, Foglio E, et al. Vascular endothelial cells and dysfunctions: role of melatonin. Front Biosci (Elite Ed). 2013;5:119-129.
57. Rizzo NR, Hank NC, Zhang J. Detecting presence of cardiovascular disease through mitochondria respiration as depicted through biophotonic emission. Redox Biol. 2016;8:11-17.
58. Rasmussen ST, Andersen JT, Nielsen TK, et al. Simvastatin and oxidative stress in humans: a randomized, double-blinded, placebo-controlled clinical trial. Redox Biol. 2016;9:32-38.
59. Ma S, Wang Y, Chen Y, et al. The role of the autophagy in myocardial ischemia/reperfusion injury. Biochim Biophys Acta. 2015;1852:271-276.
60. Ishikita A, Matoba T, Ikeda G, et al. Nanoparticle-mediated delivery of mitochondrial division inhibitor 1 to the myocardium protects the heart from ischemia-reperfusion injury through inhibition of mitochondria outer membrane permeabilization: a new therapeutic modality for acute myocardial infarction. J Am Heart Assoc. 2016;5:e003872.
61. Kozlov AV, Lancaster JR Jr, Meszaros AT, et al. Mitochondria-meditated pathways of organ failure upon inflammation. Redox Biol. 2017;13:170-181.
62. Evsyukova HV. Expression of melatonin in platelets of patients with aspirin-induced asthma. Eur J Clin Invest. 2011;41:781-784.